Global Blood Therapeutics GBT

$ 68.49 0.0%

Quarterly report 2022-Q2
added 08-08-2022

Global Blood Therapeutics Balance Sheet 2011-2024 | GBT

Annual Balance Sheet Global Blood Therapeutics

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-433 M	-262 M	79.1 M	-275 M	-198 M	-92.1 M	-149 M	-52.1 M	-3.28 M	-	-
Long Term Debt	246 M	149 M	73.6 M	-	-	-	-	-	-	-	-
Long Term Debt Current	5.67 M	4.84 M	1.87 M	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	229 M	146 M	11.1 M	11.7 M	563 K	1.56 M	103 M	28.4 M	-	-
Total Current Liabilities	88 M	79 M	71.5 M	33.8 M	26.3 M	15.5 M	10.7 M	-	-	-	-
Total Liabilities	743 M	308 M	217 M	44.8 M	37.9 M	16.1 M	12.3 M	105 M	32.1 M	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-1.29 B	-986 M	-739 M	-472 M	-298 M	-181 M	-98.5 M	-49.3 M	-28 M	-	-
Total Assets	939 M	724 M	796 M	618 M	357 M	202 M	153 M	55.8 M	6.17 M	-	-
Cash and Cash Equivalents	685 M	495 M	302 M	275 M	198 M	92.1 M	149 M	52.1 M	3.28 M	-	-
Book Value	196 M	416 M	579 M	573 M	319 M	186 M	141 M	-49.3 M	-26 M	-	-
Total Shareholders Equity	196 M	416 M	579 M	573 M	319 M	186 M	141 M	-49.3 M	-26 M	-	-

All numbers in USD currency

Quarterly Balance Sheet Global Blood Therapeutics

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	247 M	247 M	246 M	150 M	149 M	149 M	149 M	149 M	149 M	149 M	73.6 M	73.6 M	73.6 M	73.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	752 M	736 M	743 M	299 M	299 M	287 M	308 M	308 M	308 M	308 M	217 M	217 M	217 M	217 M	44.8 M	44.8 M	44.8 M	44.8 M	37.9 M	37.9 M	37.9 M	37.9 M	16.1 M	16.1 M	16.1 M	16.1 M	11.2 M	12.3 M	12.3 M	12.3 M	2.92 M	2.92 M	2.92 M	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-	-	-1.45 B	-1.37 B	-1.29 B	-1.2 B	-1.13 B	-1.06 B	-986 M	-986 M	-986 M	-986 M	-739 M	-739 M	-739 M	-739 M	-472 M	-472 M	-472 M	-472 M	-298 M	-298 M	-298 M	-298 M	-181 M	-181 M	-181 M	-181 M	-98.5 M	-98.5 M	-98.5 M	-98.5 M	-49.3 M	-49.3 M	-49.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	-	-	870 M	870 M	939 M	608 M	615 M	650 M	724 M	724 M	724 M	724 M	796 M	796 M	796 M	796 M	618 M	618 M	618 M	618 M	357 M	357 M	357 M	357 M	202 M	202 M	202 M	202 M	152 M	153 M	153 M	153 M	55.8 M	55.8 M	55.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	-	-	261 M	392 M	685 M	383 M	419 M	445 M	497 M	495 M	495 M	495 M	302 M	302 M	302 M	302 M	275 M	275 M	275 M	275 M	198 M	198 M	198 M	198 M	92.1 M	92.1 M	92.1 M	92.1 M	149 M	149 M	149 M	149 M	52.1 M	52.1 M	52.1 M	-	3.28 M	-	-	-	3.64 M	-	-	-	-	-	-	-
Book Value	-	-	118 M	134 M	196 M	308 M	316 M	363 M	416 M	416 M	416 M	416 M	579 M	579 M	579 M	579 M	573 M	573 M	573 M	573 M	319 M	319 M	319 M	319 M	186 M	186 M	186 M	186 M	141 M	141 M	141 M	141 M	52.8 M	52.8 M	52.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-	-	118 M	134 M	196 M	308 M	316 M	363 M	416 M	416 M	416 M	416 M	579 M	579 M	579 M	579 M	573 M	573 M	573 M	573 M	319 M	319 M	319 M	319 M	186 M	186 M	186 M	186 M	141 M	141 M	141 M	141 M	-49.3 M	-49.3 M	-49.3 M	-	-26 M	-	-	-	-9.35 M	-	-	-	-	-	-	-

All numbers in USD currency